- Molecular NameDalfopristin
- SynonymDalfopristina [inn-spanish]; Dalfopristine [inn-french]; Dalfopristinum [inn-latin]
- Weight690.859
- Drugbank_IDDB01764
- ACS_NO112362-50-2
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.27
- pkaN/A
- LogD (pH=7, predicted)0.44
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.94
- LogSw (predicted, AB/LogsW2.0)0.67
- Sw (mg/ml) (predicted, ACD/Labs)0.99
- No.of HBond Donors2
- No.of HBond Acceptors13
- No.of Rotatable Bonds7
- TPSA184.8
- StatusFDA approved
- AdministrationN/A
- PharmacologyA streptogramin antibiotic derived from pristinamycin IIA.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding53.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro, the transformation of the parent drugs into their major active metabolites occurs by non-enzymatic reactions and is not dependent on cytochrome-P450 or glutathione-transferase enzyme activities. Fecal excretion constitutes the main elimination route for both parent drugs and their metabolites (75-77% of dose). Urinary excretion accounts for approximately 15% of the quinupristin and 19% of the dalfopristin dose. Preclinical data in rats have demonstrated that approximately 80% of the dose is excreted in the bile and suggest that in man, biliary excretion is probably the principal route for fecal elimination.
- Half life1 h
- ExcretionN/A
- Urinary ExcretionN/A
- Clerance0.67
- ToxicityAdverse reactions with an incidence of more than 1% and possibly or probably related to Synercid administration include: infusion site reactions, nausea, vomiting, diarrhea, trombophlebitis, rash, headache, pruritis, pain.
- LD50 (rat)N/A
- LD50 (mouse)N/A